FindTrial
Sign In

A study for the interaction between NAFLD based on the genetic and atherosclerosis and the individual treatment scheme of fatty liver (Key Project)

A study for the interaction between NAFLD based on the genetic and atherosclerosis and the individual treatment scheme of fatty liver (Key Project)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-15006447
Enrollment
Unknown
Registered
2015-05-24
Start date
2014-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD and AS

Interventions

All population:Polyene Phosphatidylcholine Capsules (Yi Shanfu)

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 70 Years

Inclusion criteria

Inclusion criteria: Standard refers to "diagnosis and treatment guidelines of nonalcoholic fatty liver disease (2010 revision)"

Exclusion criteria

Exclusion criteria: Exclusion criteria were individual with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, drug-induced liver disease, liver degeneration, autoimmune liver disease, a history of alcohol consumption (>140 g/week in male or 70 g/week in female).

Design outcomes

Primary

MeasureTime frame
genetic polymorphism;—

Countries

China

Contacts

Public ContactShiying Xuan
dxyxyn@163.com+86 0532-88905508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 11, 2026